Nautilus Biotechnology (NAUT) Cash from Operations (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Cash from Operations of 13726000.0 for Q2 2026, down 4.78% sequentially from 13100000.0 in Q1 2026, and down 2.82% YoY from 14123793.74 in Q2 2025.
Nautilus Biotechnology (NAUT) Cash from Operations (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Cash from Operations for 7 years, with the latest figure at 13726000.0 in Q2 2026.
- Quarterly Cash from Operations fell 2.82% year-over-year to 13726000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 50235000.0 (up 8.18% YoY) and the FY2025 annual result came in at 50696000.0, up 14.29% from the prior year.
- Cash from Operations fell to 13726000.0 in Q2 2026 per NAUT's latest filing, from 13100000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 9565000.0 in Q3 2022 and troughed at 16266000.0 in Q1 2024.
- A 5-year average of 13010222.22 and a median of 13231500.0 in 2024 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 32.53% in 2022, down 97.27% in 2022.
- Over 5 years, Cash from Operations stood at 10377000.0 in 2022, then slumped by 33.95% to 13900000.0 in 2023, then slipped by 2.94% to 14309000.0 in 2024, then grew by 13.52% to 12375000.0 in 2025, then declined by 10.92% to 13726000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 13726000.0, 13100000.0, and 12375000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | -13.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.73 Mn |
| Jun 30, 2026 | -13.73 Mn |
| Mar 31, 2026 | -13.10 Mn |
| Mar 31, 2026 | -13.10 Mn |
| Dec 31, 2025 | -12.38 Mn |
| Dec 31, 2025 | -12.38 Mn |
| Sep 30, 2025 | -11.03 Mn |
| Sep 30, 2025 | -11.03 Mn |
| Jun 30, 2025 | -13.35 Mn |
| Jun 30, 2025 | -13.35 Mn |
| Mar 31, 2025 | -13.94 Mn |
| Mar 31, 2025 | -13.94 Mn |
| Dec 31, 2024 | -14.31 Mn |
| Dec 31, 2024 | -14.31 Mn |
| Sep 30, 2024 | -13.11 Mn |
| Sep 30, 2024 | -13.11 Mn |
| Jun 30, 2024 | -15.46 Mn |
| Jun 30, 2024 | -15.46 Mn |
| Mar 31, 2024 | -16.27 Mn |
| Mar 31, 2024 | -16.27 Mn |